Palvella Therapeutics, Inc.
PVLA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001583648
In the last 90 days, Palvella Therapeutics, Inc. insiders filed 0 open-market purchases and 5 sales; 196 institutions reported holding it in 13F filings for Q2 2026, worth $2.15B in total; no superinvestor holds it.
13F holders, Q3 2024
Institutional positions in Palvella Therapeutics, Inc. as of Sep 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 25
- +6 vs. Q2 2024
- Shares held
- 605.6K
- +256.3K (+73.4%) vs. Q2 2024
- Total value
- $10.1M
- +$6.64M (+192.8%) vs. Q2 2024
- New holders
- 8
- 3 more added
- Sold out
- 2
- 6 more reduced
1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting PVLA on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 196 | $2.15B |
| Q1 2026 | 180 | $1.64B |
| Q4 2025 | 140 | $1.02B |
| Q3 2025 | 100 | $534.5M |
| Q2 2025 | 67 | $133.2M |
| Q1 2025 | 41 | $143.4M |
| Q4 2024 | 33 | $48.4M |
| Q3 2024 | 25 | $10.1M |
| Q2 2024 | 20 | $3.57M |
| Q1 2024 | 0 | $0 |
| Q4 2023 | 0 | $0 |
| Q3 2023 | 0 | $0 |
| Q2 2023 | 0 | $0 |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q3 2024
Shares, value and share of portfolio for each institution holding Palvella Therapeutics, Inc.; share changes are against Q2 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BVF Inc | 257,626 | $4.31M | 0.13% | 00.0% | Unchanged |
| ADAR1 Capital Management, LLC | 144,641 | $2.40M | 0.40% | +144,641 | New |
| BML Capital Management, LLC | 42,130 | $698.5K | 0.41% | +42,130 | New |
| Lynx1 Capital Management LP | 37,436 | $620.7K | 0.22% | −6,063−13.9% | Reduced |
| Renaissance Technologies LLC | 32,171 | $533.4K | 0.00% | +20,700+180.5% | Added |
| CM Management, LLC | 22,500 | $373.1K | 0.30% | +22,500 | New |
| Frazier Life Sciences Management, L.P. | 15,942 | $266.9K | 0.01% | +15,942 | New |
| BlackRock, Inc. | 12,938 | $214.5K | 0.00% | +12,938 | New |
| Geode Capital Management, LLC | 11,981 | $200.6K | 0.00% | +1,358+12.8% | Added |
| Citadel Advisors LLC | 11,686 | $195.6K | 0.00% | +11,686 | New |
| Vanguard Group Inc | 11,342 | $189.9K | 0.00% | 00.0% | Unchanged |
| Acadian Asset Management LLC | 3,013 | $49.0K | 0.00% | −7,814−72.2% | Reduced |
| Citigroup Inc | 1,108 | $18.5K | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 348 | $5.77K | 0.00% | −1,378−79.8% | Reduced |
| Group One Trading, L.P. | 312 | $5.22K | 0.00% | −11−3.4% | Reduced |
| US Bancorp | 138 | $2.29K | 0.00% | −20−12.7% | Reduced |
| Morgan Stanley | 91 | $1.51K | 0.00% | +9+11.0% | Added |
| Barclays PLC | 63 | $1.04K | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 60 | $995 | 0.00% | 00.0% | Unchanged |
| JPMorgan Chase & Co | 26 | $435 | 0.00% | −1−3.7% | Reduced |
| Truvestments Capital LLC | 14 | $232 | 0.00% | +14 | New |
| Bank of America Corp | 13 | $215 | 0.00% | 00.0% | Unchanged |
| Advisor Group Holdings, Inc. | 7 | $116 | 0.00% | 00.0% | Unchanged |
| Allworth Financial LP | 5 | $83 | 0.00% | 00.0% | Unchanged |
| Danske Bank A/S | 2 | $33 | 0.00% | +2 | New |
| Tower Research Capital LLC (TRC) | 0 | $0 | 0.00% | −334−100.0% | Sold out |
| Royal Bank of Canada | 0 | $0 | 0.00% | −4−100.0% | Sold out |
| BlackRock Inc. | – | – | – | – | Not filed |